Premium
Differential expression of CD180 and IgM by B‐cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes
Author(s) -
Porakishvili N.,
Kulikova N.,
Jewell A. P.,
Youinou P. Y.,
Yong K.,
Nathwani A.,
Heelan B.,
Duke V.,
Hamblin T. J.,
Wallace P.,
Ely P.,
Clark E. A.,
Lydyard P. M.
Publication year - 2005
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2005.05775.x
Subject(s) - surface immunoglobulin , antibody , chronic lymphocytic leukemia , biology , gene , phenotype , microbiology and biotechnology , b cell , immunoglobulin heavy chain , immunoglobulin m , immunology , gene expression , immunoglobulin gene , immunoglobulin g , genetics , leukemia
Summary We have studied the surface expression of the Toll‐like receptor family member CD180 on cells from 78 patients with B‐chronic lymphocytic leukaemia (B‐CLL). B‐CLL cells had variable levels of CD180 expression, but this was always less than that expressed by normal blood B cells and was stable for 24 months. Significantly higher levels of CD180 were expressed by B‐CLL cells with mutated IGVH genes compared with those using unmutated IGVH genes. This was in contrast to the higher levels of expression of surface immunoglobulin M by B‐CLL cells using unmutated, rather than mutated IGVH genes. CD180 was functional on B‐CLL cells from some of the patients, as shown by the increased expression of CD86 following incubation in vitro with anti‐CD180. The differential expression of CD180 amongst B‐CLL patients is one more marker that may define more precisely the different biological properties of this heterogeneous disease.